7.4 Multimodal Therapy & Treatment Sequencing
Key Takeaways
- Neoadjuvant therapy downstages tumors, enables organ preservation, and provides an in vivo test of sensitivity, and pathologic complete response after neoadjuvant treatment is a strong prognostic marker in triple-negative and HER2-positive breast cancer.
- Concurrent chemoradiation produces better local control than sequential therapy but markedly amplifies mucositis, esophagitis, dermatitis, and myelosuppression.
- Common radiosensitizers include cisplatin, fluorouracil and capecitabine, mitomycin-C, gemcitabine, and cetuximab.
- Bevacizumab and other anti-VEGF agents must be held approximately 4 to 6 weeks before and after elective surgery because they impair wound healing and increase bleeding and perforation risk.
- Radiation recall dermatitis is an inflammatory reaction reappearing in a previously irradiated field after a later systemic agent, most classically an anthracycline or taxane, and is distinct from acute radiation dermatitis.
7.4 Multimodal Therapy & Treatment Sequencing
Blueprint focus: ONCC Domain II.G — Multimodal therapy. The exam tests why a sequence is chosen and what the sequence does to toxicity and to perioperative safety.
The Vocabulary of Sequence
| Term | Definition | Purpose |
|---|---|---|
| Neoadjuvant (primary systemic) therapy | Systemic therapy or chemoradiation given before definitive local therapy | Downstage to make resection possible, enable organ preservation, treat micrometastatic disease early, and test in vivo sensitivity |
| Adjuvant therapy | Therapy given after definitive local therapy in a patient with no measurable disease | Eradicate micrometastatic disease and reduce recurrence |
| Concurrent chemoradiation | Chemotherapy given at the same time as radiation | Chemotherapy acts as a radiosensitizer, improving local control |
| Sequential therapy | Chemotherapy then radiation, or the reverse, without overlap | Lower toxicity when a patient cannot tolerate concurrent treatment |
| Consolidation therapy | Additional therapy after the patient has achieved remission | Deepen and prolong response — for example durvalumab after chemoradiation in unresectable stage III NSCLC |
| Maintenance therapy | Lower-intensity ongoing therapy after response | Delay progression — for example PARP inhibitor maintenance in ovarian cancer |
| Total neoadjuvant therapy (TNT) | All chemotherapy and chemoradiation delivered before surgery | Used in locally advanced rectal cancer; raises complete response rates and enables watch-and-wait in selected patients |
| Salvage therapy | Treatment after failure of definitive therapy | Attempt cure or durable control after relapse |
Why Neoadjuvant Therapy Is Often Preferred
1. It converts an inoperable tumor into an operable one. Locally advanced rectal cancer, borderline resectable pancreatic cancer, and bulky breast tumors are the standard examples.
2. It enables organ preservation.
- Breast: downstaging can convert a mastectomy candidate into a lumpectomy candidate, and can convert a node-positive axilla into one manageable with sentinel node biopsy alone.
- Larynx: induction chemotherapy or chemoradiation preserves speech versus total laryngectomy.
- Bladder: neoadjuvant cisplatin-based chemotherapy before cystectomy improves survival, and trimodality therapy (maximal transurethral resection plus chemoradiation) preserves the bladder in selected patients.
- Extremity sarcoma: preoperative radiation permits limb-sparing resection.
- Rectum: total neoadjuvant therapy can produce a clinical complete response permitting nonoperative watch-and-wait management in carefully selected patients.
3. It provides prognostic information you cannot obtain any other way. Pathologic complete response (pCR) — no residual invasive disease in the breast and nodes — is strongly associated with excellent long-term outcome in triple-negative and HER2-positive breast cancer. Just as importantly, residual disease identifies patients who need escalated adjuvant therapy, which is why adjuvant capecitabine after residual triple-negative disease and adjuvant ado-trastuzumab emtansine after residual HER2-positive disease became standard.
The trade-off: neoadjuvant treatment removes the pathologic stage of the untreated tumor, and a non-responding tumor may progress to inoperability. Complete radiographic and clinical staging plus clip placement in the tumor bed and any biopsied node must be done before the first dose.
Concurrent Chemoradiation
Concurrent delivery is standard for definitive treatment of locally advanced cervical, anal, head and neck, esophageal, rectal, and unresectable non-small cell lung cancer.
Radiosensitizers work by impairing repair of radiation-induced DNA damage, arresting cells in radiosensitive phases, and reducing hypoxia.
| Agent | Typical setting |
|---|---|
| Cisplatin | Head and neck, cervix, esophagus, lung |
| Fluorouracil or capecitabine | Rectum, anus, esophagus, stomach |
| Mitomycin-C plus fluorouracil | Anal canal (the Nigro regimen, which made abdominoperineal resection unnecessary in most patients) |
| Gemcitabine | Pancreas, bladder — a potent sensitizer requiring careful dosing |
| Cetuximab | Head and neck when cisplatin is contraindicated |
| Temozolomide | Glioblastoma, concurrently and then adjuvantly |
Toxicity is amplified, not merely added. Expect worse mucositis and dysphagia in head and neck and esophageal fields, worse esophagitis in thoracic fields, worse diarrhea and proctitis in pelvic fields, worse dermatitis in the treated skin, and worse myelosuppression. Anticipatory management — prophylactic antiemetics, aggressive oral care, early nutrition and swallowing evaluation, consideration of a feeding tube before weight loss becomes severe, and skin care protocols — determines whether the patient completes therapy. Treatment interruptions compromise local control, so preventing them is a clinical priority rather than a comfort measure.
Perioperative Timing Rules
These intervals are tested because getting them wrong causes wound dehiscence, anastomotic leak, and hemorrhage.
| Agent or modality | Interval before elective surgery | Interval before resuming |
|---|---|---|
| Bevacizumab and other anti-VEGF agents | 4 to 6 weeks | 4 to 6 weeks, and only after complete wound healing |
| Cytotoxic chemotherapy | Generally 3 to 4 weeks, and counts must have recovered | After wound healing, commonly 3 to 4 weeks |
| Neoadjuvant radiation (rectum) | Commonly 6 to 12 weeks to allow tumor regression and inflammation to settle | — |
| Immune checkpoint inhibitors | Individualized; no fixed interval, but active immune-related toxicity should be controlled first | After resolution of toxicity |
| Tyrosine kinase inhibitors | Typically held for a period based on half-life, often about 1 week | After wound healing |
Bevacizumab is the one that appears most often on examinations, because VEGF inhibition directly impairs the angiogenesis required for wound healing and raises the risk of gastrointestinal perforation, hemorrhage, and dehiscence.
Radiation Recall and Radiation Enhancement
- Radiation recall dermatitis is an inflammatory reaction that appears in a previously irradiated field when a systemic agent is given days to years later. Anthracyclines and taxanes are the classic triggers, and gemcitabine is another. It is managed by holding the offending drug and providing topical care.
- Radiation enhancement (radiosensitization) occurs when the systemic agent is given during or within about a week of radiation, intensifying acute toxicity in the field.
- The distinction is timing: recall happens after radiation has finished, enhancement happens around the same time.
The APRN's Role Across Modalities
Multimodal care fails at the seams between specialties. The nurse practitioner tracks the whole sequence: confirming that staging and clip placement preceded neoadjuvant therapy; that response assessment occurred at the planned interval; that the perioperative hold was actually observed; that adjuvant therapy is started within the intended window after surgery; that escalated adjuvant therapy is offered when residual disease is found; and that the patient understands why treatment is being given in this order. A patient who does not know why they are getting chemotherapy before surgery is the patient most likely to disengage between modalities.
A patient with metastatic colorectal cancer receiving FOLFOX plus bevacizumab is scheduled for elective resection of a solitary liver metastasis. What is the mandatory recommendation regarding bevacizumab?
A patient with triple-negative breast cancer completes neoadjuvant chemotherapy, and the surgical specimen shows a 1.4 cm residual invasive tumor with one positive node. How should the nurse practitioner interpret and act on this result?
Three months after completing chest wall radiation, a patient receives her first dose of doxorubicin. Six days later she develops erythema, edema, and desquamation confined precisely to the previously irradiated field. What is this reaction?